Neuroleptics and Prolactin

A Second Look
  • Walter Armin Brown


In 1955, shortly after its introduction as an antipsychotic, clinicians noted that chlorpromazine occasionally induced galactorrhea (Hooper et al., 1961). It was not until 1971, however, that chlorpromazine, and other neuroleptics as well, were found to regularly elevate serum prolactin (PRL) (Beumont et al., 1974). This observation and our current understanding of its mechanism awaited a series of conceptual and methodological advances.


Schizophrenic Patient Tardive Dyskinesia Extrapyramidal Side Effect Radioreceptor Assay Neuroleptic Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Asnis, G. M., Sachar, E. J., Langer, G., Halpern, F. S., and Fink, M., 1979, Normal prolactin responses in tardive dyskinesia, Psychopharmacology 66:247.PubMedCrossRefGoogle Scholar
  2. Beumont, P. J. V., Gelder, M. G., Friesen, H. G., Harris, G. W., MacKinnon, P. C. B., Mandelbrote, B. M., and Wiles, D. H., 1974, The effects of phenothiazines on endocrine function. I. Patients with inappropriate lactation and amenorrhoea, Br. J. Psychiatry 124:413.PubMedCrossRefGoogle Scholar
  3. Bjorndal, N., Bjerre, M., Gerlach, J., Kristjansen, P., Magelund, G., Oestrich, I. H., and Waehrens, J., 1980, High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin, Psychopharmacology 67:17.PubMedCrossRefGoogle Scholar
  4. Bowers, M. B., Jr., and Heninger, G. R., 1981, Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment, Psychiatry Res. 4:285.PubMedCrossRefGoogle Scholar
  5. Brown, W. A., and Laughren, T. P., 1980, Growth hormone release and the tardive dyskinesia of neuroleptic withdrawal, Lancet 1:259.PubMedCrossRefGoogle Scholar
  6. Brown, W. A., and Laughren, T. P., 1981a, Low serum prolactin and early relapse following neuroleptic withdrawal, Am. J. Psychiatry 183:237.Google Scholar
  7. Brown, W. A., and Laughren, T. P., 1981b, Tolerance to the prolactin elevating effect of neuroleptics, Psychiatry Res. 5:317.PubMedCrossRefGoogle Scholar
  8. Brown, W. A., Laughren, T. P., Chisholm, E., and Williams, B. W., 1982, Low serum neuroleptic levels predict relapse in schizophrenic patients, Arch. Gen. Psych. 39:998.CrossRefGoogle Scholar
  9. Burt, D. R., Creese, I., and Snyder, S. H., 1977, Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain, Science 196:326.PubMedCrossRefGoogle Scholar
  10. Busch, D. A., Fang, V. S., and Meltzer, H. Y., 1979, Serum prolactin levels following intramuscular chlorpromazine: Two- and three-hour response as predictors of six-hour response, Psychiatry Res. 1:153.PubMedCrossRefGoogle Scholar
  11. Calil, H. M., Avery, D. H., Hollister, L. E., Creese, I., and Snyder, S. H., 1979, Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations, Psychiatry Res. 1:39.PubMedCrossRefGoogle Scholar
  12. Casey, D. E., and Denney, D., 1977, Pharmacological characterization of tardive dyskinesia, Psychopharmacology 54:1.PubMedCrossRefGoogle Scholar
  13. Cheung, C. Y., and Weiner, R. I., 1978, In vitro supersensitivity of the anterior pituitary to dopamine inhibition of prolactin secretion, Endocrinology 102:1614.PubMedCrossRefGoogle Scholar
  14. Cohen, B. M., Lipinski, J. F., Harris, P. Q., Pope, H. G., Jr., and Friedman, M., 1980, Clinical use of the radioreceptor assay for neuroleptics, Psychiatry Res. 2:173.PubMedCrossRefGoogle Scholar
  15. Creese, I., Burt, D. R., and Snyder, S. H., 1976, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs, Science 192:481.PubMedCrossRefGoogle Scholar
  16. Danon, A., Dikstein, S., and Sulman, F. G., 1963, Stimulation of prolactin secretion by perphenazine in pituitary-hypothalamus organ culture, Proc. Soc. Exp. Biol. Med. 114:366.PubMedGoogle Scholar
  17. Davis, J. M., Erickson, S., and Dekirmenjian, H., 1972, Plasma levels of anti-psychotic drugs and clinical response, in: Psychopharmacology: A Generation of Progress (M. A. Lipton, A. DiMascio, and K. F. Killman, eds.), pp. 905–915, Raven Press, New York.Google Scholar
  18. DeRivera, J. L., Lal, S., Ettigi, P., Hontela, S., Muller, H. F., and Friesen, H. G., 1976, Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups, Clin. Endocrinol. (Oxford) 5:273.CrossRefGoogle Scholar
  19. Dotti, A., Lostia, O., Rubino, I. A., Bersant, G., Carilli, L., and Zorretta, D., 1981, The prolactin response in patients receiving neuroleptic therapy: The effect of fluphenazine decanoate, Prog. Neuro-Psychopharmacol. 5:69.CrossRefGoogle Scholar
  20. Evans, L. E. J., Beumont, P. J. V., Luttrell, B., Henniker, A. J., and Penny, J., 1980, Prolactin response as a guide to neuroleptic treatment of schizophrenia, Prog. Reprod. Biol. 6:260.Google Scholar
  21. Glazer, W. M., Moore, D. C., Bowers, M. B., and Brown, W. A., 1981, Serum prolactin and tradive dyskinesia, Am. J. Psychiatry 138:1493.PubMedGoogle Scholar
  22. Gruen, P. H., Sachar, E. J., Langer, G., Altman, N., Leifer, M., Frantz, A., and Halpern, F. S., 1978a, Prolactin responses to neuroleptics in normal and schizophrenic subjects, Arch. Gen. Psychiatry 35:108.PubMedCrossRefGoogle Scholar
  23. Gruen, P. H., Sachar, E. J., Altman, N., Langer, G., Tabrizi, M. A., and Halpern, F. S., 1978b, Relation of plasma prolactin to clinical response in schizophrenic patients, Arch. Gen. Psychiatry 35:1222.PubMedCrossRefGoogle Scholar
  24. Hogarty, G. E., Schooler, N. R., Ulrich, R., Mussare, F., Ferro, P., and Herron, E., 1979, Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride, Arch. Gen. Psychiatry 36:1283.PubMedCrossRefGoogle Scholar
  25. Hollister, L. E., 1977, Antipsychotic medications and the treatment of schizophrenia, in: Psycho-pharmacology: From Theory to Practice (J. Barchas, P. Berger, R. Ciaranello, and G. Elliott, eds.), pp. 121–150, Oxford University Press, London.Google Scholar
  26. Hooper, J. H., Jr., Welch, V. C., Point, P., and Schackelford, R. T., 1961, Abnormal lactation associated with tranquilizing drug therapy. J. Am. Med. Assoc. 178:506.CrossRefGoogle Scholar
  27. Kolakowska, T., Wiles, D. H., Gelder, M. G., and McNeilly, A. S., 1976, Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment, Psychopharmacology 49:101.PubMedGoogle Scholar
  28. Lal, H., Brown, W. A., Drawbaugh, R., Hynes, M., and Brown, G., 1977, Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine, Life Sci. 20:101.PubMedCrossRefGoogle Scholar
  29. Laughren, T. P., Brown, W. A., and Williams, B. W., 1979, Serum prolactin and clinical state during neuroleptic treatment and withdrawal, Am. J. Psychiatry 136:108.PubMedGoogle Scholar
  30. Linnolia, M., Viukari, M., Vaisanen, K., and Auvinen, J., 1980, Plasma neuroleptic and prolactin levels in mentally retarded patients, Acta Pharmacol. Toxicol. 46:159.CrossRefGoogle Scholar
  31. Meltzer, H. Y., and Fang, V. S., 1976, The effect of neuroleptics on serum prolactin in schizophrenic patients, Arch. Gen. Psychiatry 33:279.PubMedCrossRefGoogle Scholar
  32. Meltzer, H. Y., Busch, D. A., Creese, I. R., Snyder, S. H., and Fang, V. S., 1981, Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls Psychiatry Res. 5:95.PubMedCrossRefGoogle Scholar
  33. Naber, D., Fischer, H., and Ackenheil, M., 1979, Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: Development of tolerance?, Commun. Psychopharmacol. 3:59.PubMedGoogle Scholar
  34. Nikitopoulou, G., Thorner, M., Crammer, J., and Lader, M., 1977, Prolactin and psychophysiologic measures after single doses of thioridazine, Clin. Pharmacol. Ther. 21:422.PubMedGoogle Scholar
  35. Ohman, R., and Axelsson, R., 1978, Relationship between prolactin response and antipsychotic effect of thioridazine in psychiatric patients, Eur. J. Clin. Pharmacol. 14:111.PubMedCrossRefGoogle Scholar
  36. Pasteels, J. L., 1961, Secretion of prolactin by the pituitary in tissue culture, C. R. Acad. Sci. 253:2140.Google Scholar
  37. Post, R. M., and Goodwin, F. K., 1975, Time dependent effects of phenothiazines on dopamine turnover in psychiatric patients, Science 190:488.PubMedCrossRefGoogle Scholar
  38. Rao, V. A. R., Bishop, M., and Coppen, A., 1980, Clinical state, plasma levels of haloperidol and prolactin: A correlation study in chronic schizophrenia, Br. J. Psychiatry 137:518.PubMedCrossRefGoogle Scholar
  39. Rubin, R. T., and Forster, B., 1980, Haloperidol stimulation of prolactin secretion: How many blood samples are needed to define the hormone response?, Commun. Psychopharmacol. 4:41.PubMedGoogle Scholar
  40. Rubin, R. T., Poland, R. E., O’Conner, D., Gouin, P. R., and Tower, B. B., 1976, Selective neuroendocrine effects of low-dose haloperidol in normal adult men, Psychopharmacology 47:135.CrossRefGoogle Scholar
  41. Rubin, R. T., Forsman, A., Heykants, J., Ohman, R., Tower, B., and Michiels, M., 1980, Serum haloperidol determinations in psychiatric patients: Comparison of methods and correlation with serum prolactin level, Arch. Gen. Psychiatry 37:1069.PubMedCrossRefGoogle Scholar
  42. Seeman, P., 1980, Brain dopamine receptors, Pharmacol. Rev. 32:229.PubMedGoogle Scholar
  43. Smith, R. C., Tamminga, C. A., Crayton, J. W., Dekirmenjian, H., and Davis, J. M., 1979, Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients, Psychopharmacology 66:29.PubMedCrossRefGoogle Scholar
  44. Tamminga, C. A., Smith, R. C., Pandey, G., Frohman, L. A., and Davis, J. M., 1977, A neuroendocrine study of supersensitivity in tardive dyskinesia, Arch. Gen. Psychiatry 34:1199.PubMedCrossRefGoogle Scholar
  45. Tarsy, D., and Baldessarini, R. J., 1977, The pathophysiologic basis of tardive dyskinesia, Biol. Psychiatry 12:431.PubMedGoogle Scholar
  46. Wiles, D. H., Kolakowska, T., McNeilly, A. S., Mandelbrote, B. M., and Gelder, M. G., 1976, Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment, Psychol. Med. 6:407.PubMedCrossRefGoogle Scholar
  47. Wistedt, B., 1981, Withdrawal of long-acting neuroleptics in schizophrenic outpatients: Clinical and biological findings, Acta Univ. Ups. 397:1.Google Scholar
  48. Wistedt, B., Wiles, D., and Kolakowska, T., 1981, Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics, Lancet I:1163.CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Walter Armin Brown
    • 1
  1. 1.Neuroendocrine Research Program, Providence Veterans Administration Medical Center, and Department of PsychiatryBrown UniversityProvidenceUSA

Personalised recommendations